Molecular Formula: C107H166N26O26S2
Molecular Weight: 2296.74 g/mol
Peptide purity: Greater than 98%
Other details: No TFA Salt, No Mannitol
Peptide KCF-18 is a Multifunctional Therapeutic Agent.
Designed based on the receptors of key inflammatory cytokines - TNF-α, IL-1β, and IL-6, KCF-18 is a multifunctional peptide. It acts as a binding decoy, concurrently blocking these cytokines and inhibiting their binding to their respective receptors. This unique mechanism of action allows KCF-18 to achieve triple cytokine inhibition, a feature that sets it apart from other therapeutic peptides.
One of the key benefits of KCF-18 is its potential to diminish the risk of vascular inflammation. It does this by decreasing the release of plasma cytokines and directly inhibiting monocyte adhesion to the endothelium. This dual action not only reduces inflammation but also helps protect the vascular system, making KCF-18 a potential therapeutic agent for vascular diseases.
In addition to its anti-inflammatory properties, KCF-18 has also shown promise in the field of immunotherapy. It has been found to reduce the number of transmigrating THP-1 cells induced by cytokines. This suggests that KCF-18 could play a role in modulating immune responses, opening up new possibilities for its use in treating immune-related diseases.
The structure of KCF-18 is another factor contributing to its therapeutic potential. The peptide is comprised of six positively charged N-terminal amino acids from TNFR1, six positively charged and hydrophobic middle amino acids from IL-1R1, and six negatively charged C-terminal amino acids from IL-6Rα. This unique composition may contribute to its multifunctional properties and its ability to interact with multiple cytokine receptors.
Shinn-Jongf Jiang et al., "A potential peptide derived from cytokine receptors can bind proinflammatory cytokines as a therapeutic strategy for anti-inflammation" [Nature]
Chun-Chun Chang et al., "A Multitarget Therapeutic Peptide Derived From Cytokine Receptors Based on in Silico Analysis Alleviates Cytokine-Stimulated Inflammation" [Frontiers]
Hung-Jen Shih et al., "Simultaneous Inhibition of Three Major Cytokines and Its Therapeutic Effects: A Peptide-Based Novel Therapy against Endotoxemia in Mice" [MDPI]
This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.
All product information provided on this website is for informational and educational purposes only.